FDA Center for Drug Evaluation & Research Issues Warning Letter to Safrel Pharmaceuticals
August 19, 2026
August 19, 2026
WASHINGTON, Aug. 19 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Safrel Pharmaceuticals LLC from its Center for Drug Evaluation and Research:
* * *
Recipient: Mr. Dipen Patel, Chief Executive Officer, Safrel Pharmaceuticals LLC, 178 Ridge Road, Dayton, NJ 08810-2532, United States
Issuing Office: Center for Drug Evaluation and Research (CDER), United States
Warning Lette . . .
* * *
Recipient: Mr. Dipen Patel, Chief Executive Officer, Safrel Pharmaceuticals LLC, 178 Ridge Road, Dayton, NJ 08810-2532, United States
Issuing Office: Center for Drug Evaluation and Research (CDER), United States
Warning Lette . . .